Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Vectura Group plc
Headquarters: Chippenham, Wiltshire, United Kingdom
Website: N/A
Year Founded: 1997
Status: Acquired
BioCentury | Apr 12, 2024
Management Tracks
Disagreement over Biosecure Act pushed Shipley out of BIO
Plus: Melita Sun Jung named CBO at Terns, and updates from Zentalis, Pharvaris, Nuevocor and Stalicla
BioCentury | Oct 6, 2022
Management Tracks
LifeMine rounds out team with Stahl, Plamondon
Plus Theolytics adds Actelion vet Oakley as CFO, and updates from Capricorn, Cambrian,
BioCentury | May 26, 2022
Emerging Company Profile
Kinaset: targeting JAK to treat both asthma phenotypes
With a $40M series A and former head of Pulmatrix Robert Clarke as CEO, Kinaset is going upstream in the inflammatory pathway to treat both major types of asthma
BioCentury | Aug 18, 2021
Deals
Quick Takes Aug. 17: InnoCare gains China rights to Incyte’s Monjuvi
Plus: Neuroblastoma approval for BeiGene, priority review for Agios’ mitapivat, Arctic Vision, Vectura, AnaptysBio and more
BioCentury | Aug 10, 2021
Product Development
Aug. 9 Quick Takes: BioNTech earnings drive shares to another all-time high
Plus NDA ‘deficiencies’ sink Axsome shares, Hutchmed-Epizyme, Polivy and more
BioCentury | Jul 10, 2021
Deals
July 9 Quick Takes: Novo-built Muna launches with $73M series A; plus Sigilon, bluebird, Vectura, BeiGene, Bayer and more
Launching with a $73 million series A round, small molecule neurodegeneration play Muna Therapeutics is based on technology from the labs of two professors: Simon Glerup from Denmark's Aarhus
BioCentury | May 27, 2021
Deals
May 26 Quick Takes: Akili raises $160M to take digital therapeutic to market; plus venture rounds for Engine and Clear, Lyell’s IPO and a $1.4B takeout for Vectura
With $110 million in a series D equity round plus a $50 million credit facility, Akili Interactive Labs Inc. will accelerate its go-to-market strategy for digital therapeutic EndeavorRx to treat ADHD.
BioCentury | May 7, 2021
Product Development
COVID Quick Takes: ACIP readies to discuss vaccine for ages 12-15; plus Novavax, Moderna, Vectura
In a signal that COVID vaccines could soon be available for Americans as young as 12, CDC’s Advisory Committee on Immunization Practices (ACIP) has revealed that the emergency meeting
BioCentury | Nov 30, 2020
Finance
Kinaset jumps into severe asthma with $40M to develop inhaled JAK inhibitor
Kinaset is launching with a $40 million series A led by 5AM Ventures and Atlas Venture with participation from Gimv to develop an inhaled immunomodulator that will compete with biologics in
BioCentury | Mar 12, 2020
Management Tracks
Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more
Items per page:
1 - 10 of 259